Johnson & Johnson $JNJ Stock: Private Management Group Inc. Decreases Position

Private Management Group Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 5.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,112 shares of the company’s stock after selling 3,215 shares during the period. Private Management Group Inc.’s holdings in Johnson & Johnson were worth $14,590,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Clear Wave Wealth Management LLC lifted its stake in Johnson & Johnson by 2.0% in the third quarter. Clear Wave Wealth Management LLC now owns 5,191 shares of the company’s stock valued at $1,374,000 after buying an additional 100 shares during the last quarter. Kohmann Bosshard Financial Services LLC grew its position in shares of Johnson & Johnson by 9.1% during the third quarter. Kohmann Bosshard Financial Services LLC now owns 2,630 shares of the company’s stock worth $696,000 after acquiring an additional 220 shares during the last quarter. Joseph Group Capital Management grew its position in shares of Johnson & Johnson by 27.2% during the third quarter. Joseph Group Capital Management now owns 749 shares of the company’s stock worth $198,000 after acquiring an additional 160 shares during the last quarter. Fulcrum Asset Management LLP increased its holdings in shares of Johnson & Johnson by 57.4% in the 3rd quarter. Fulcrum Asset Management LLP now owns 32,760 shares of the company’s stock valued at $8,766,000 after acquiring an additional 11,945 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Johnson & Johnson by 5.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 712,721 shares of the company’s stock valued at $184,352,000 after acquiring an additional 38,654 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 2.0%

Shares of JNJ opened at $281.86 on Tuesday. The company has a market capitalization of $678.53 billion, a PE ratio of 42.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.73. The stock has a fifty day moving average of $266.18 and a two-hundred day moving average of $248.62.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is presently 81.21%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Leerink Partners decreased their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. Wells Fargo & Company raised their price target on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Finally, Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.